NCT06161025招募中2 期
A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 860
- 试验地点
- 288
- 主要终点
- Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Assessment (Part A)
研究概览
简要总结
This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.
详细描述
This study will focus on R-DXd in participants with platinum-resistant, high-grade ovarian, primary peritoneal, or fallopian tube cancer. R-DXd is an antibody-drug conjugate that specifically binds to CDH6, which is overexpressed in tumor cells. The Phase 2 dose-optimization part of the study (Part A) intends to define the recommended dose based on safety and efficacy, while the Phase 3 (Part B) part of the study will compare R-DXd with Investigator's choice of chemotherapy and further evaluate efficacy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Sign and date the informed consent form prior to the start of any study-specific qualification procedures.
- •Age ≥18 years or the minimum legal adult age (whichever is greater) at the time the informed consent form is signed.
- •Participants with histologically or cytologically documented high-grade serous ovarian cancer (OVC), high-grade endometrioid OVC, primary peritoneal cancer, or fallopian tube cancer.
- •For Phase 2 (Part A) Participants must have at least 1 lesion, not previously irradiated, amenable to biopsy, and must consent to provide a pretreatment biopsy and on-treatment biopsy tissue sample (on-treatment biopsy sample not required for the Phase 3 part of the study). Fresh pretreatment biopsy may be waived for subjects who consent to provide an archival tumor tissue sample from a lesion not previously irradiated, performed within 6 months of consent and performed after treatment with their most recent cancer therapy regimen.
- •For Phase 2 (Part A): Has received at least 1 but no more than 3 prior systemic lines of anticancer therapy. For Phase 3 (Part B): Has received at least 1 but no more than 4 prior systemic lines of anticancer therapy:
- •Neoadjuvant +/-adjuvant considered 1 line of therapy.
- •Maintenance therapy (eg, bevacizumab, poly-ADP ribose polymerase [PARP] inhibitors) will be considered part of the preceding line of therapy.
- •Therapy changed due to toxicity in the absence of progression will be considered part of the same line.
- •Hormonal therapy will be counted as a separate line of therapy, unless it was given as maintenance.
- •At least 1 line of therapy containing bevacizumab, unless the subject is not eligible for treatment with bevacizumab due to precautions/intolerance. Note: Subjects must have progressed radiologically on or after their most recent line of systemic therapy. Biochemical progression will not be considered progression for this study.
- •Has platinum-resistant disease. If a subject had only 1 line of platinum therapy, must have received at least 4 cycles of platinum, must have had a best response of not PD, and then progressed between >90 and ≤180 days after the date of the last dose of platinum If a subject had 2 or 4 lines of platinum therapy, must have received at least 2 cycles of platinum and have progressed on or within 180 days after the date of the last dose of platinum.
- •If mirvetuximab soravtansine (MIRV) is locally available: Has had prior treatment with MIRV for participants with documented high-folate receptor alpha expression, unless the participant is not eligible for treatment with mirvetuximab soravtansine due to precautions/intolerance, or if the treatment is not approved or available locally.
- •Has at least 1 measurable lesion evaluated by computed tomography or magnetic resonance imaging according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per investigator assessment.
- •Eastern Cooperative Oncology Group performance status of 0 or
- •Has adequate organ and bone marrow function as assessed by local laboratory (within 14 days before start of study drug administration).
- •Is willing and able to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures and study restrictions.
- •For Phase 3 (Part B) only: Subjects must be eligible for one of the treatments included in the investigator's choice of chemotherapy arm.
排除标准
- •Has clear cell, mucinous, or sarcomatous histology, mixed tumors containing any histology, or low-grade/borderline OVC. (Note for Phase 3 [Part B]: seromucinous, low-grade serous carcinoma or ovarian sarcoma, carcinosarcoma and undifferentiated carcinoma are excluded.)
- •Inadequate washout period before Cycle 1 Day 1, defined as follows:
- •Major surgery <28 days
- •Radiation therapy <28 days (if palliative stereotactic radiation therapy without abdominal radiation, ≤14 days)
- •Systemic anticancer therapy (including antibody-drug therapy, retinoid therapy, and hormonal therapy) <28 days or 5 half-lives, whichever is shorter, before starting study drug
- •Chloroquine/hydroxychloroquine <14 days
- •Exposure to another investigational drug within 28 days prior to start of study treatment or current participation in other therapeutic investigational procedures
- •Clinically active brain metastases, spinal cord compression, or leptomeningeal carcinomatosis, defined as untreated or symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms. Subjects with untreated and asymptomatic brain metastases or subjects with treated brain metastases who are no longer symptomatic and who require no treatment with steroids may be included in the study if they have recovered from the acute toxic effect of radiotherapy, at the investigator's discretion A minimum of 2 weeks must have elapsed between the end of radiotherapy and randomization and there should be no evidence of progression or need for steroid treatment or anticonvulsants for at least 2 weeks prior to randomization. Note: If there is a history or suspicion of central nervous system. Note: If there is a history or suspicion of central nervous system metastasis, a CT scan of the head or MRI of the brain must be performed at baseline.
- •Any of the following within the past 6 months prior to randomization: cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic event.
- •Uncontrolled or significant cardiovascular disease, including the following:
- •QT interval corrected with Fridericia's formula interval >470 ms.
- •Diagnosed or suspected long QT syndrome.
- •History of clinically relevant ventricular arrhythmias, such as ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes.
- •The participant has bradycardia of less than 50 bpm, unless the subject has a pacemaker.
- •History of second- or third-degree heart block. Candidates with a history of heart block may be eligible if they currently have pacemakers and have no history of fainting or clinically relevant arrhythmia with pacemakers.
- •Myocardial infarction within 6 months prior to screening.
- •Uncontrolled angina pectoris within 6 months prior to screening.
- •New York Heart Association Class 3 or 4 congestive heart failure.
- •Left ventricular ejection fraction <50% or institutional lower limit of normal as measured by echocardiography or multigated acquisition (MUGA) scan.
- •Coronary/peripheral artery bypass graft within 6 months prior to screening
- •Uncontrolled hypertension (HgCTCAE Grade ≥3 hypertension as per NCI-CTCAE version 5.0).
- •Complete left or right bundle branch block.
- •Has a history of (noninfectious) ILD/pneumonitis that required corticosteroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
- •Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (ie, pulmonary emboli within 3 months of the study enrollment, severe asthma, severe chronic obstructive pulmonary disease (COPD), restrictive lung disease, pleural effusion, etc) and any autoimmune, connective tissue, or inflammatory disorders with potential pulmonary involvement (eg, rheumatoid arthritis, Sjogren's syndrome, sarcoidosis, etc), or prior pneumonectomy.
- •Chronic steroid treatment (>10 mg/day), with the exception of the following:
- •Inhaled steroids for asthma or COPD
- •Mineralocorticoids (eg, fludrocortisone) for subjects with orthostatic hypotension
- •Topical steroids for mild skin conditions
- •Low-dose supplemental corticosteroids for adrenocortical insufficiency
- •Premedication for treatment groups and/or premedication in case of any hypersensitivity
- •Intra-articular steroid injections
- •History of malignancy other than epithelial OVC, primary peritoneal cancer, or fallopian tube cancer within 3 years prior to enrollment, with the exception of those with a negligible risk of metastasis or death (eg, 5-year OS rate >90%) and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, nonmelanoma skin carcinoma, ductal carcinoma in situ, or Stage 1 uterine cancer).
- •Unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to NCI-CTCAE Version 5.0, Grade ≤1 or baseline. Note: Subjects may be enrolled with chronic, stable Grade 2 toxicities (defined as no worsening to Grade >2 for 3 months prior to randomization and managed with SOC treatment) that the investigator deems related to previous anticancer therapy, following discussion with the Sponsor, such as the following:
- •Chemotherapy-induced neuropathy
- •Endocrinopathies, which may include hypothyroidism, hyperthyroidism, Type 1 diabetes, hyperglycemia, and adrenal insufficiency
- •Skin pigmentation (vitiligo)
- •For Phase 2 (Part A): Prior exposure to other CDH6-targeted agents or an ADC that consists of an exatecan derivative that is a topoisomerase I inhibitor (eg, trastuzumab deruxtecan or datopotamab deruxtecan). For Phase 3 (Part B): Prior exposure to other CDH6-targeted agents or an antibody-drug conjugate containing a topoisomerase I inhibitor.
- •History of hypersensitivity to any excipients in the R-DXd or any known contraindication to treatment with, including hypersensitivity to, the study drug(s).
- •Has an active or uncontrolled human immunodeficiency virus (HIV) infection.
- •Has any evidence of severe or uncontrolled systemic diseases (including active bleeding diatheses or active infection, substance abuse) or other factors that, in the investigator's opinion, makes it undesirable for the subject to participate in the study or which would jeopardize compliance with the protocol. Screening for chronic conditions is not required.
- •Has an active or uncontrolled hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Hepatitis B and Hepatitis C Screening tests are required.
- •Subjects are eligible if:
- •Hepatitis B virus surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization.
- •History of hepatitis C infection: eligible if the HCV viral load is below the level of detection in the absence of antiviral therapy during the previous 4 weeks.
- •Have normal transaminase values, or, if liver metastases are present, abnormal transaminases with a result of AST/ALT <3 × ULN, which are not attributable to HCV infection.
- •Female who is pregnant or breastfeeding or intends to become pregnant during the study.
- •Psychological, social, familial, or geographical factors that would prevent regular follow-up.
- •Prior or ongoing clinically relevant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the subject; alter the absorption, distribution, metabolism, or excretion of the study drug; or confound the assessment of study results.
- •Has a history of receiving live-attenuated vaccine (messenger RNA [mRNA] and replication-deficient adenoviral vaccines are not considered attenuated live vaccines) within 30 days prior to the first exposure to study intervention.
- •For Phase 3 (Part B) only: Has clinical symptoms or radiographic evidence of intestinal obstruction.
- 另有 1 项未显示
研究组 & 干预措施
Part A: R-DXd 5.6 mg/kg Q3W
Experimental
Participants will be randomized to receive intravenous R-DXd administered at a dose of 5.6 mg/kg every 3 weeks (Q3W).
干预措施: R-DXd (Drug)
Part B: Investigator's Choice
Active Comparator
Participants will be randomized to receive intravenous treatment with investigator's choice of paclitaxel, pegylated liposomal doxorubicin (PLD), or topotecan.
干预措施: Paclitaxel (Drug)
Part B: Investigator's Choice
Active Comparator
Participants will be randomized to receive intravenous treatment with investigator's choice of paclitaxel, pegylated liposomal doxorubicin (PLD), or topotecan.
干预措施: PLD (Drug)
Part A: R-DXd 4.8mg/kg Q3W
Experimental
Participants will be randomized to receive intravenous R-DXd administered at a dose of 4.8 mg/kg every 3 weeks (Q3W).
干预措施: R-DXd (Drug)
Part B: R-DXd RP3D Q3W
Experimental
Participants will be randomized to receive intravenous R-DXd administered at the Recommended Phase 3 Dose (RP3D) every 3 weeks (Q3W).
干预措施: R-DXd (Drug)
Part B: Investigator's Choice
Active Comparator
Participants will be randomized to receive intravenous treatment with investigator's choice of paclitaxel, pegylated liposomal doxorubicin (PLD), or topotecan.
干预措施: Topotecan (Drug)
Part A: R-DXd 6.4 mg/kg Q3W
Experimental
Participants will be randomized to receive intravenous R-DXd administered at a dose of 6.4 mg/kg every 3 weeks (Q3W).
干预措施: R-DXd (Drug)
结局指标
主要结局
Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Assessment (Part A)
时间窗: From date of randomization to data cut off, up to 18 months
The ORR was defined as the percentage of participants with confirmed Complete Response (CR) or Partial Response (PR), by BICR assessment based on RECIST version 1.1.
Progression-free Survival (PFS) Based on BICR Assessment (Part B)
时间窗: From date of randomization to data cut off, up to 26 months
PFS is defined as the time from the date of randomization to the date of disease progression, defined as the first documented radiological progression or death due to any cause, whichever comes first.
Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Assessment (Part A)
时间窗: From date of randomization to data cut off, up to 18 months
The ORR was defined as the percentage of participants with confirmed Complete Response (CR) or Partial Response (PR), by BICR assessment based on RECIST version 1.1.
Progression-free Survival (PFS) Based on BICR Assessment (Part B)
时间窗: From date of randomization to data cut off, up to 26 months
PFS is defined as the time from the date of randomization to the date of disease progression, defined as the first documented radiological progression or death due to any cause, whichever comes first.
次要结局
- Pharmacokinetic (PK) Analysis: Terminal Half-Life (t1/2) of R-DXd(From first dose to data cut off, up to 40 months)
- Time to Next Treatment (TTNT)(From date of randomization to data cut off, up to 40 months)
- Progression-free Survival 2 (PFS2) Based on Investigator Assessment(From date of randomization to data cut off, up to 40 months)
- Percentage of Participants With Cancer Antigen 125 (CA-125) Response Rate(From baseline to data cut off, up to 40 months)
- Cadherin-6 (CDH6) protein expression in tumor tissue as determined by immunochemistry assay and correlation with ORR, DoR, PFS and OS(From baseline to data cut off, up to 40 months)
- Objective Response Rate (ORR) Based on Investigator Assessment(From date of randomization to data cut off, up to 30 months)
- Duration of Response (DOR)(From date of randomization to data cut off, up to 40 months)
- Disease Control Rate (DCR)(From date of randomization to data cut off, up to 40 months)
- Overall Survival (OS)(From date of randomization to data cut off, up to 40 months)
- Number of participants with Treatment-emergent Adverse Events (TEAEs)(From first dose to data cut off, up to 40 months)
- Pharmacokinetic (PK) Analysis: Maximum Plasma Drug Concentration (Cmax) of R-DXd(From first dose to data cut off, up to 40 months)
- Pharmacokinetic (PK) Analysis: Time to Reach Maximum Plasma Drug Concentration (Tmax) of R-DXP(From first dose to data cut off, up to 40 months)
- Pharmacokinetic (PK) Analysis: Area Under the Concentration-Time Curve (AUC) of R-DXd(From first dose to data cut off, up to 40 months)
- Percentage of Participants With Treatment Emergent Antidrug Antibody (ADA)(From baseline to data cut off, up to 40 months)
- Overall Survival (OS)(From date of randomization to data cut off, up to 40 months)
- Objective Response Rate (ORR) Based on Investigator Assessment(From date of randomization to data cut off, up to 30 months)
- Duration of Response (DOR)(From date of randomization to data cut off, up to 40 months)
- Progression-free Survival (PFS) Based on BICR and Investigator Assessment(From date of randomization to data cut off, up to 30 months)
- Disease Control Rate (DCR)(From date of randomization to data cut off, up to 40 months)
- Time to Next Treatment (TTNT)(From date of randomization to data cut off, up to 40 months)
- Progression-free Survival 2 (PFS2) Based on Investigator Assessment(From date of randomization to data cut off, up to 40 months)
- Percentage of Participants With Cancer Antigen 125 (CA-125) Response Rate(From baseline to data cut off, up to 40 months)
- Number of participants with Treatment-emergent Adverse Events (TEAEs)(From first dose to data cut off, up to 40 months)
- Pharmacokinetic (PK) Analysis: Maximum Plasma Drug Concentration (Cmax) of R-DXd(From first dose to data cut off, up to 40 months)
- Pharmacokinetic (PK) Analysis: Time to Reach Maximum Plasma Drug Concentration (Tmax) of R-DXP(From first dose to data cut off, up to 40 months)
- Pharmacokinetic (PK) Analysis: Area Under the Concentration-Time Curve (AUC) of R-DXd(From first dose to data cut off, up to 40 months)
- Percentage of Participants With Treatment Emergent Antidrug Antibody (ADA)(From baseline to data cut off, up to 40 months)
- Pharmacokinetic (PK) Analysis: Terminal Half-Life (t1/2) of R-DXd(From first dose to data cut off, up to 40 months)
- Change from Baseline in Abdominal/gastrointestinal (GI) Symptoms (Part B)(From baseline to Week 12 and up to data cut off, up to 40 months)
- Change from Baseline in Fatigue/Pain Symptoms (Part B)(From baseline to data cut off, up to 40 months)
- Time to Deterioration in Fatigue/Pain Symptoms (Part B)(From baseline to data cut off, up to 40 months)
- Time to Deterioration in GI Symptoms (Part B)(From baseline to data cut off, up to 40 months)
- Time to Deterioration in Disease Impacts (Part B)(From baseline to data cut off, up to 40 months)
- Change from Baseline in Disease Impacts (Part B)(From baseline to data cut off, up to 40 months)
- Cadherin-6 (CDH6) protein expression in tumor tissue as determined by immunochemistry assay and correlation with ORR, DoR, PFS and OS(From baseline to data cut off, up to 40 months)
研究者
研究点 (288)
Loading locations...
相似试验
招募中
3 期
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerSmall Cell Lung CancerNCT06203210Daiichi Sankyo540
招募中
3 期
Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)Gastric CancerNCT04787354Hallym University Medical Center976
进行中（未招募）
3 期
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic AlterationsMetastatic Non Small Cell Lung CancerNCT05215340Daiichi Sankyo740
招募中
3 期
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic AlterationsNon-Small Cell Lung CancerNCT06357533AstraZeneca675
已完成
不适用
Comparison Between Laparoscopic Ovarian Diathermy and Clomiphene Citrate in Women With Anovulatory PCOSPolycystic Ovary SyndromeNCT00220545Sheffield Teaching Hospitals NHS Foundation Trust72